Skip to main content
SpringerLink
Log in
Book cover

Multiple Risk Factors in Cardiovascular Disease pp 85–92Cite as

PAI-1 and the Risk of Cardiovascular Disease

  • Chapter

Part of the book series: Medical Science Symposia Series ((MSSS,volume 12))

Abstract

Among the list of coronary risk factors, it has recently been proposed that impairment of the fibrinolytic system detected in plasma, due to increased plasminogen activator inhibitor -1 (PAI-1) level, could predict complications of atherosclerosis.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Collen D, Lijnen HR. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 1991; 78: 3114–24.

    PubMed  CAS  Google Scholar 

  2. Reilly CF, Fujita T, Hutzelmann JE, Mayer EJ, Shebuski RJ. Plasminogen activator inhibitor 1 suppresses endogenous fibrinolysis in a canine model of pulmonary-embolism. Circulation 1991; 84: 287–92.

    Article  PubMed  CAS  Google Scholar 

  3. Vaughan DE, Declerck PJ, Van Houtte E, De Mol M, Collen D. Reactivated recombinant plasminogen activator inhibitor 1 (rPAI-1) effectively prevents thrombolysis in vivo. Thromb Haemostas 1992; 68: 60–63.

    CAS  Google Scholar 

  4. Biemond BJ, Levi M, Coronel R, Janse MJ, Ten Cate JW, Pannekoek H. Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Effect of a plasminogen activator inhibitor type 1 neutralizing monoclonal antibody. Circulation 1995; 91: 1175–81.

    Article  PubMed  CAS  Google Scholar 

  5. Erickson LA, Fici GJ, Lund JE, Boyle TP, Polites HG, Marotti KR. Development of venous occlusions in mice transgenic for the PAI-I gene. Nature 1990; 346: 74–76.

    Article  PubMed  CAS  Google Scholar 

  6. Carmeliet P, Bouche A, Schoonjans L, et al. Physiological consequences of loss of plasminogen activator gene function in mice. Nature 1994; 368: 419–24.

    Article  PubMed  CAS  Google Scholar 

  7. Carmeliet P, Bouche A, De Clercq C, et al. Biological effects of disruption of the tissue-type plasminogen activator, urokinase type plasminogen activator and plasminogen activator inhibitor-1 genes in mice. Ann NY Acad Sci 1995; 748: 367–82.

    Article  PubMed  CAS  Google Scholar 

  8. Stefansson S, Lawrence DA. The serpin PAI-1 inhibits cell migration by blocking integrin avb3 binding to vitronectin. Nature 1996; 323: 441–43.

    Article  Google Scholar 

  9. Deng G, Curriden SA, Wang S, Rosenberg S, Loskutoff DJ. Is plasminogen activator inhibitor 1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol 1996; 134: 1563–71.

    Article  PubMed  CAS  Google Scholar 

  10. Juhan-Vague I, Alessi MC. Plasminogen activator inhibitor 1 and atherothrombosis. Thromb Haemostas 1993; 70: 138–43.

    CAS  Google Scholar 

  11. Prinz MH, Hirsh J. A critical review of the relationship between impaired fibrinolysis and myocardial infarction. Amer Heart J 1991; 122: 545–51.

    Article  Google Scholar 

  12. Rocha E, Paramo JA. The relationship between impaired fibrinolysis and coronary heart disease. A role for PAI-1. Fibrinolysis 1994; 8: 294–303.

    Article  CAS  Google Scholar 

  13. Schneiderman J, Sawdey MS, Keeton MR, et al. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA 1992; 89: 6998–7002.

    Article  PubMed  CAS  Google Scholar 

  14. Chomiki N, Henry M, Alessi MC, Anfosso F, Juhan-Vague I. Plasminogen activator inhibitor 1 expression in human liver and healthy or atherosclerotic vessel walls. Thromb Haemostas 1994; 72: 44–53.

    CAS  Google Scholar 

  15. Lupu F, Bergonzelli GE, Heim DA, et al. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb 1993; 13: 1090–1100.

    Article  PubMed  CAS  Google Scholar 

  16. Juhan-Vague I, Alessi MC. Fibrinolysis and risk of coronary artery disease. Fibrinolysis 1996; 10: 127–36.

    CAS  Google Scholar 

  17. Meade TW, Ruddock V, Stirling Y, Chakrabarti T, Miller GJ. Fibrinolytic activity, clotting factors and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342: 1076–79

    Article  PubMed  CAS  Google Scholar 

  18. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue type plasminogen activator and risk of myocardial infarction. Lancet 1993; 341: 1165–68.

    Article  PubMed  CAS  Google Scholar 

  19. Jansson JH, Nilsson TK, Olofsson BO. Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris. Eur Heart J 1991; 12: 157–61.

    PubMed  CAS  Google Scholar 

  20. Jansson JH, Olofsson BO, Nilsson TK. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease. A 7 year follow up. Circulation 1993; 88: 2030–34.

    Article  PubMed  CAS  Google Scholar 

  21. Hamsten A, De Faire U, Walldius G, et al. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet 1987; II: 3–9.

    Article  Google Scholar 

  22. Gram J, Jespersen J, Kluft C, Rijken DC. On the usefulness of fibrinolysis variables in the characterization of a risk group for myocardial infarction. Acta Med Scand 1987; 221: 149–53.

    Article  PubMed  CAS  Google Scholar 

  23. Cortellaro M, Cofrancesco E, Boschetti C, et al., for the PLAT Group. Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients: A case-control study. Arterioscler Thromb 1993; 13: 1412–17.

    Article  PubMed  CAS  Google Scholar 

  24. Cimmiello C. Tissue type plasminogen activator and risk of myocardial infarction. Lancet 1993; 342: 48–49.

    Article  Google Scholar 

  25. Munkvad S, Gram J, Jespersen J. A depression of active tissue plasminogen activator in plasma characterizes patients with unstable angina pectoris who develop myocardial infarction. Eur Heart J 1990; 11: 525–28.

    PubMed  CAS  Google Scholar 

  26. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332: 635–41.

    Article  PubMed  CAS  Google Scholar 

  27. Juhan-Vague I, Pyke SDM, Alessi MC, Jespersen J, Haverkate F, Thompson SG. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. Circulation 1996; 94: 2057–63.

    Article  PubMed  CAS  Google Scholar 

  28. Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia 1991; 34: 457–62.

    Article  PubMed  CAS  Google Scholar 

  29. Juhan-Vague I, Thompson SG, Jespersen J. Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. Arterioscler Thromb 1993; 13: 1865–73.

    Article  PubMed  CAS  Google Scholar 

  30. Potter van Loon BJ, Kluft C, Radder JK, Blankenstein MA, Meinders AE. The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. Metabolism 1993; 42: 945–49.

    Article  Google Scholar 

  31. Eliasson M, Evrin PE, Lundblad D. Fibrinogen and fibrinolytic variables in relation to anthropometry, lipids and blood pressure. The Northern Sweden MONICA Study. J Clin Epidemiol 1994; 47: 513–24.

    Article  PubMed  CAS  Google Scholar 

  32. Vague P, Juhan-Vague I, Chabert V, Alessi MC, Atlan C. Fat distribution and plasminogen activator inhibitor activity in non diabetic obese women. Metabolism 1989; 38: 913–15.

    Article  PubMed  CAS  Google Scholar 

  33. Landin K, Stigendal L, Eriksson E, et al. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism 1990; 39: 1044–48.

    Article  PubMed  CAS  Google Scholar 

  34. Schneider DJ, Sobel BE. Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type 1: Implications for vascular disease by hyperinsulinemic states. Proc Nat Acad Sci USA 1991; 88: 9959–63.

    Article  PubMed  CAS  Google Scholar 

  35. Mc Gill JB, Schneider DJ, Artken CL, Lucore CL, Sobel BE. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes 1994; 43: 104–9.

    Article  CAS  Google Scholar 

  36. Hamsten A, Karpe F, Bavenholm P, Silveira A. Interactions amongst insulin, lipoproteins and haemostatic function relevant to coronary heart disease. J Int Med 1994; 236: 75–88.

    CAS  Google Scholar 

  37. Nagi DK, Hendra TJ, Ryle AJ, et al. The relationships of concentrations of insulin, intact proinsulin and 32–33 split proinsulin with cardiovascular risk factors in type 2 (non insulin dependent) diabetic subjects. Diabetologia 1990; 33: 532–37.

    Article  PubMed  CAS  Google Scholar 

  38. Juhan-Vague I, Messi MC, Joly P, et al. Plasma plasminogen activator inhibitor 1 in angina pectoris. Influence of plasma insulin and acute-phase response. Arteriosclerosis 1989; 9: 362–67.

    Article  PubMed  CAS  Google Scholar 

  39. Haverkate F, Thompson SG, Duckett F. Haemostasis factors in angina pectoris: Relation to gender, age and acute-phase reaction. Thromb Haemostas 1995; 73: 561–67.

    CAS  Google Scholar 

  40. Reaven GO. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595–607.

    Article  PubMed  CAS  Google Scholar 

  41. Zimmet P. The epidemiology of diabetes mellitus and related conditions. In: Alberti KGMM, Krall CP, editors. The Diabetes Annual 6. Amsterdam: Elsevier, 1991: 1–19.

    Google Scholar 

  42. Ferrannini E, Haffner SM, Mitchell BD, Stern MP. Hyperinsulinemia. The key feature of a cardiovascular and metabolic syndrome. Diabetologia 1991; 34: 416–22.

    Article  PubMed  CAS  Google Scholar 

  43. Eschwege E, Richard JL, Thibult N, et al. Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels. The Paris Prospective Study, ten years later. Horm Metab Res 1985; 15: 41–46.

    CAS  Google Scholar 

  44. Pyörälä K, Savolainen E, Kaukola S, Haapakoski J. Plasma insulin as coronary heart disease risk factor: Relationship to other risk factors and predictive value during 9-year follow-up of the Helsinki Policemen Study population. Acta Med Scand 1985; 701 (Suppl.): 38–52.

    Google Scholar 

  45. Desprès JP, Lamarche B, Mauriège P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Eng J Med 1996; 334: 952–57.

    Article  Google Scholar 

  46. Sundell IB, Dahlgren S, Ranby M, Lundin E, Stenling R, Nilsson TK. Reduction of elevated plasminogen activator inhibitor levels during modest weight loss. Fibrinolysis 1989; 3: 51–53.

    Article  CAS  Google Scholar 

  47. Vague P, Juhan-Vague I, Alessi MC, Badier C, Valadier J. Metformin decreases the high plasminogen activator inhibition capacity, plasma insulin and triglyceride levels in non diabetic obese subjects. Thromb Haemostas 1987; 57: 326–28.

    CAS  Google Scholar 

  48. Landin K, Tengborn L, Smith U. Treating insulin resistance in hypertension with Metformin reduces both blood pressure and metabolic risk factors. J Int Med 1991; 229: 181–87.

    Article  CAS  Google Scholar 

  49. Estelles A, Aznar J, Tormo G, Sapena P, Tonno V, Espana F. Influence of a rehabilitation sports program on the fibrinolytic activity of patients after myocardial infarction. Thromb Res 1989; 55: 203–12.

    Article  PubMed  CAS  Google Scholar 

  50. Gris JC, Schved JF, Aguilar-Martinez P, Arnaud A, Sanchez N. Impact of physical training on plasminogen activator inhibitor activity in sedentary men. Fibrinolysis 1990; 4: 97–98.

    CAS  Google Scholar 

  51. Folsom AR, Qamhieh HT, Wing RR, et al. Impact of weight loss on plasminogen activator inhibitor (PAI-1) factor VII, and other hemostatic factors in moderately over weight adults. Arterioscler Thromb 1993; 13: 162–69.

    Article  PubMed  CAS  Google Scholar 

  52. Alessi MC, Parrot G, Guenoun E, Scelles V, Vague P, Juhan-Vague I. Relation between plasma PAI activity and Adipsin levels. Thromb Haemostas 1995; 74: 1200–1202.

    CAS  Google Scholar 

  53. Sawdey S, Loskutoff DJ. Regulation of murine type 1 plasminogen activity inhibitor (PAI-1) gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor a and transforming growth factor b. J Clin Invest 1991; 8: 1346–53.

    Article  Google Scholar 

  54. Samad F, Yamamoto K, Loskutoff D.J. Distribution and regulation of plasminogen activator inhibitor 1 in murine adipose tissue in vivo. J Clin Invest 1996; 97: 37–46.

    Article  PubMed  CAS  Google Scholar 

  55. Lundgren CH, Brown SL, Nordt TD, Sobel BE, Fujii S. Elaboration of type 1 plasminogen activator inhibitor from adipocytes. A potential pathogenetic link between obesity and cardiovascular disease. Circulation 1996; 93: 106–10.

    Article  PubMed  CAS  Google Scholar 

  56. Samad F. Loskutoff DJ. Tissue distribution and regulation of plasminogen activator inhibitor-1 in obese mice. Mol Med 1996; 2: 568–82.

    PubMed  CAS  Google Scholar 

  57. Shimomura I, Funahashi T, Takahashi M, et al. Enhanced expression of PAI-1 in visceral fat: Possible contributor to vascular disease in obesity. Nature Medicine 1996; 2: 800–803.

    Article  PubMed  CAS  Google Scholar 

  58. Shimomura I, Funahashi T, Takahashi M, et al. Enhanced expression of PAI-1 in visceral fat: Possible contributor to vascular disease in obesity. Nature Medicine 1996; 2: 800–803.

    Article  PubMed  CAS  Google Scholar 

  59. Björntorp P. “Portal” adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. Arteriosclerosis 1990;10:493–96.

    Article  PubMed  Google Scholar 

  60. Larsson B, Svärdsud DK, Welin L, Wilheimsen L, Björntorp P, Tibbin G. Abdominal adipose tissue distribution, obesity and risk of cardiovascular disease and death: 13 year follow-up of participants in the study of men born in 1913. Br Med J 1984; 288: 1401–04.

    Article  CAS  Google Scholar 

  61. Sundell IB, Nilsson TK, Ranby M, Hallman G, Hellsten G. Fibrinolytic variables are related to age, sex, blood pressure, and body build measurements: A cross-sectional study in Norsjö, Sweden. J Clin Epidemiol 1989: 42: 719–23.

    Article  PubMed  CAS  Google Scholar 

  62. Cigolini M, Targher G, Bergamo Andreis IA, Tonoli M, Agostino G, De Sandre G. Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men. Arterioscler Thromb Vasc Biol 1996; 16: 368–74.

    Article  PubMed  CAS  Google Scholar 

  63. Dawson S, Hamsten A, Wiman B, Henney A, Humphries S. Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb 1991; 11: 183–90

    Article  PubMed  CAS  Google Scholar 

  64. Dawson SJ, Wiman B, Hamsten A, Green F, Hamphries S, Henney AM. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor 1 (PAI-1) gene respond differently to interleukin 1 in HepG2 cells. J Biol Chem 1993; 268: 10739–45.

    PubMed  CAS  Google Scholar 

  65. Dawson SJ, Wiman B, Hamsten A, Green F, Hamphries S, Henney AM. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor 1 (PAI-1) gene respond differently to interleukin 1 in HepG2 cells. J Biol Chem 1993; 268: 10739–45.

    PubMed  CAS  Google Scholar 

  66. Ye S, Green FR, Scarabin PY, et al. The 4G/5G genetic polymorphism in the promoter \of the plasminogen activator inhibitor-1 (PAI-1) associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Thromb Haemostas 1995; 74: 837–41.

    CAS  Google Scholar 

  67. Panahloo A, Mohamed-Ali V, Lane A, Green F, Humphries SE, Yudkin JS. Determinants of plasminogen activator 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene. Diabetes 1995; 44: 37–42.

    Article  PubMed  CAS  Google Scholar 

  68. Eriksson P, Kallin B, van’t Hooft, Bavenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995; 92: 1851–55.

    Article  PubMed  CAS  Google Scholar 

  69. Mansfield MW, Strickland MH, Grant PJ. Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor 1 in Caucasian patients with non insulin dependent diabetes mellitus. Thromb Haemostas 1995; 74: 842–48.

    CAS  Google Scholar 

  70. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Miletich JP. Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men. Circulation 1997; 95: 59–62.

    Article  PubMed  CAS  Google Scholar 

  71. Henry M, Tregouët DA, Alessi MC, et al Family study of metabolic and genetic determinants of PAI-1 activity and PAI-1 antigen plasma concentrations. The Stanislas cohort study. Thromb Haemostas XVIth ISTH Congress, Florence 1997, Abstract.

    Google Scholar 

  72. Charlton PA, Faint RW, Bent F, et al. A series of low molecular weight inhibitors of plasminogen activator inhibitor (PAI-1) increase fibrinolysis and protect against thrombus formation in the rat. Abstract. Thromb Haemostas 1995; 73: 1005.

    Google Scholar 

Download references

Authors
  1. Irène Juhan-Vague
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marie Christine Alessi
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Cornell University Medical College, 1300 York Avenue, Room F-105, New York, NY, USA

    Antonio M. Gotto Jr.

  2. National Heart, Lung, and Blood Institute, NIH, Bethesda, MD, USA

    C. Lenfant

  3. Institute of Pharmacological Sciences, University of Milan, Via Balzaretti 9, 20133, Milan, Italy

    Rodolfo Paoletti  & A. L. Catapano  & 

  4. Giovanni Lorenzini Medical Foundation, Houston, TX, USA

    A. S. Jackson

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Juhan-Vague, I., Alessi, M.C. (1998). PAI-1 and the Risk of Cardiovascular Disease. In: Gotto, A.M., Lenfant, C., Paoletti, R., Catapano, A.L., Jackson, A.S. (eds) Multiple Risk Factors in Cardiovascular Disease. Medical Science Symposia Series, vol 12. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-5022-4_10

Download citation

  • DOI: https://doi.org/10.1007/978-94-011-5022-4_10

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-6108-7

  • Online ISBN: 978-94-011-5022-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation